Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo Nordisk in the obesity drug race. While Novo’s shares have struggled this year, Lilly has projected roughly 25 percent growth, underscoring just how dramatically the balance of power has shifted in the booming GLP-1 market.

Please provide your email address to receive an email when new articles are posted on . The use of low dead space syringes was associated with a 76% reduction in the odds of hepatitis C virus infection among people who inject drugs, according to a study of ...

As of 2023, Orange County remains the largest county by population in the United States without an operational syringe services program (SSP). Over 40 years of evidence have demonstrated that SSPs are highly effective in preventing the spread of HIV among ...

Renewing and sustaining syringe exchange programs is essential to protecting public health, saving lives and maintaining the progress we've made.